Maxim Group set a $5.00 target price on Cytori Therapeutics (NASDAQ:CYTX) in a research note issued to investors on Monday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.

CYTX has been the subject of a number of other reports. Zacks Investment Research upgraded Cytori Therapeutics from a sell rating to a hold rating in a research note on Tuesday, January 2nd. B. Riley restated a hold rating on shares of Cytori Therapeutics in a research note on Tuesday, November 7th.

Cytori Therapeutics (CYTX) remained flat at $$0.40 on Monday. 1,627,600 shares of the company traded hands, compared to its average volume of 3,251,157. Cytori Therapeutics has a twelve month low of $0.22 and a twelve month high of $2.13. The company has a market capitalization of $14.84, a P/E ratio of -0.44 and a beta of 3.21.

Cytori Therapeutics (NASDAQ:CYTX) last issued its earnings results on Thursday, November 9th. The biotechnology company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. The business had revenue of $1.77 million during the quarter, compared to analyst estimates of $2.04 million. Cytori Therapeutics had a negative return on equity of 228.21% and a negative net margin of 367.33%. During the same period in the prior year, the company posted ($0.26) earnings per share. equities analysts expect that Cytori Therapeutics will post -0.62 EPS for the current fiscal year.

In related news, major shareholder Bank Sa Swissquote sold 100,000 shares of the company’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $0.38, for a total value of $38,000.00. Following the completion of the transaction, the insider now directly owns 5,496,655 shares in the company, valued at $2,088,728.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.90% of the company’s stock.

An institutional investor recently raised its position in Cytori Therapeutics stock. Sabby Management LLC boosted its stake in shares of Cytori Therapeutics Inc (NASDAQ:CYTX) by 28.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,626,807 shares of the biotechnology company’s stock after acquiring an additional 355,504 shares during the quarter. Sabby Management LLC owned 4.69% of Cytori Therapeutics worth $1,789,000 as of its most recent SEC filing. 7.39% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Maxim Group Analysts Give Cytori Therapeutics (CYTX) a $5.00 Price Target” was published by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.watchlistnews.com/maxim-group-analysts-give-cytori-therapeutics-cytx-a-5-00-price-target/1820275.html.

Cytori Therapeutics Company Profile

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.